QuidelOrtho launches QUICKVUE Influenza + SARS Test
The QUICKVUE Influenza + SARS test is designed for professional use to detect and differentiate between flu A/B and COVID-19 in 10–15 minutes
2 Oct 2025Product news
QUICKVUE Influenza + SARS Test
QuidelOrtho Corporation is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.
The QUICKVUE Influenza + SARS Test is designed to deliver rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens from a single patient sample, providing results in as fast as 10 minutes. This capability can help clinicians distinguish between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes.
Key features and benefits:
- Triple detection capability: Differentiates influenza A/B and COVID-19 in one test.
- Fast results: Clear results available in as fast as 10 minutes at the point of care.
- Professional use: Designed for CLIA-waived and moderate/high-complexity lab settings.
- Efficient workflow: Easy-to-collect nasal swab, streamlined processing and clear result window.
- Affordable access: Cost-effective visual combo test.
The launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho's portfolio of respiratory solutions, including the SOFIA™ 2 Flu + SARS Antigen FIA, by offering a visually read option alongside QuidelOrtho's instrumented version and reinforces QuidelOrtho's market leadership in point-of-care respiratory testing.
The QUICKVUE Influenza + SARS Test is available in the United States through QuidelOrtho's existing distribution channels and is not intended for in-home use.
"Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable and efficient tool to differentiate between COVID-19 and influenza in minutes," said Tammi Ranalli, PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho.
"This innovation reflects QuidelOrtho's commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections.," she added.